Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Insulin icodec
insulin 287 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose level 1 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 2 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 3 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 4 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 5 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 6 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 7 | EXPERIMENTAL | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Name | Type | Description |
|---|---|---|
| insulin 287 | DRUG | Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp. |
| insulin glargine | DRUG | Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels. |
| placebo | DRUG | Oral placebo adminstered corresponding to insulin 287 treatment |
Inclusion Criteria: * Body mass index 18.0-28.0 kg/m\^2 * Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investig...
Insulin 287 is an investigational small molecule drug being developed by Novo Nordisk A/S for diabetes. It is designed as an agonist of the insulin receptor (INSR). It has completed a Phase 1 clinical trial in healthy subjects, and it is not an approved therapy.
Insulin 287 targets the insulin receptor, also known as INSR. It acts as an agonist at this receptor. The insulin receptor mediates the metabolic effects of insulin, and agonism of INSR is the mechanism under investigation for this small molecule in diabetes.
Insulin 287 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this investigational small molecule agonist of the insulin receptor.
Insulin 287 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved for any indication, including diabetes.
Insulin 287 has been studied in one completed Phase 1 trial, NCT01809184. That trial investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of NNC0148-0000-0287 in healthy subjects. It enrolled 84 participants in Germany, was randomized, double blind, and controlled, and included male healthy volunteers aged 18 years and older.
Insulin 287 is being investigated for diabetes, including type 2 diabetes mellitus. It is an experimental small molecule insulin receptor agonist in Phase 1 development. It is not approved or available for treating diabetes, and its safety and efficacy have not been established.